Latest News
- Jan. 20, 2012
- Cell Therapeutics, Inc. Expects That the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) May Issue an Opinion on the Marketing Authorization Application ("MAA") on Pixuvri™ in Mid-February
- Jan. 03, 2012
- FDA's Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
- Dec. 19, 2011
- Cell Therapeutics Retires Remaining Convertible Debt
- Dec. 13, 2011
- Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML)
Pipeline Updates
Dec. 10, 2011Cell Therapeutics ASH Analyst/Investor Meeting
11:15 a.m. PSTWebcast
Nov. 11, 2011Cell Therapeutics, Inc. (CTI) to hold Annual Meeting
1 p.m. ESTInformation about Annual Meeting
Annual Meeting Webcast
Oct. 25, 2011Cell Therapeutics, Inc. (CTI) to Report Third Quarter 2011 Financial Results
8:30 a.m. EDTWebcast
Oct. 25, 2011Cell Therapeutics, Inc. (CTI) to Present at 10th Annual BIO Investor Forum
2:30 p.m. EDTWebcast
Sept. 12, 2011Cell Therapeutics, Inc. (CTI) to Present at 13th Annual Rodman & Renshaw Healthcare Conference
2 p.m. EDTWebcast
July 28, 2011Second Quarter Financial Results
8:30 a.m. EDTHear Webcast
June 14, 2011 PIXANTRONE appeal update Read press release
May, 3, 2011Conference Call Update on PIXANTRONE
View Webcast
June 4, 2011Investor Webcast - TOSEDOSTAT OverviewView Webcast
